For help on how to get the results you want, see our search tips.
404 results
-
List item
Human medicine European public assessment report (EPAR): Inrebic (updated)
fedratinib dihydrochloride monohydrate, Myeloproliferative Disorders, Primary Myelofibrosis
Date of authorisation: 08/02/2021,
, 
, Authorised, Last updated: 09/06/2021
-
List item
Human medicine European public assessment report (EPAR): Ibrance (updated)
palbociclib, Breast Neoplasms
Date of authorisation: 09/11/2016,, Revision: 12, Authorised, Last updated: 09/06/2021
-
List item
Human medicine European public assessment report (EPAR): Xeljanz (updated)
tofacitinib citrate, Arthritis, Rheumatoid
Date of authorisation: 21/03/2017,
Date of refusal: 25/04/2013,
, , Revision: 18, Authorised, Last updated: 08/06/2021
-
List item
Human medicine European public assessment report (EPAR): Keytruda (updated)
Pembrolizumab, Melanoma, Hodgkin Disease, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urologic Neoplasms, Squamous Cell Carcinoma of Head and Neck
Date of authorisation: 17/07/2015,, Revision: 35, Authorised, Last updated: 07/06/2021
-
List item
Human medicine European public assessment report (EPAR): Ketoconazole HRA (updated)
Ketoconazole, Cushing Syndrome
Date of authorisation: 18/11/2014,, 
, , Revision: 10, Authorised, Last updated: 07/06/2021
-
List item
Human medicine European public assessment report (EPAR): Nexpovio (updated)
Selinexor, Multiple Myeloma
Date of authorisation: 26/03/2021,, 
, Authorised, Last updated: 07/06/2021
-
List item
Human medicine European public assessment report (EPAR): Quofenix (updated)
delafloxacin meglumine, Skin Diseases, Bacterial
Date of authorisation: 16/12/2019,, Revision: 3, Authorised, Last updated: 04/06/2021
-
List item
Human medicine European public assessment report (EPAR): Polivy (updated)
polatuzumab vedotin, Lymphoma, B-Cell
Date of authorisation: 16/01/2020,, , , Revision: 3, Authorised, Last updated: 04/06/2021
-
List item
Human medicine European public assessment report (EPAR): Rinvoq (updated)
upadacitinib, Arthritis, Rheumatoid
Date of authorisation: 16/12/2019,, Revision: 4, Authorised, Last updated: 04/06/2021
-
List item
Human medicine European public assessment report (EPAR): Ontozry (updated)
cenobamate, Epilepsy
Date of authorisation: 26/03/2021,, Revision: 1, Authorised, Last updated: 03/06/2021
-
List item
Human medicine European public assessment report (EPAR): Xospata (updated)
gilteritinib fumarate, Leukemia, Myeloid, Acute
Date of authorisation: 24/10/2019,, , Revision: 1, Authorised, Last updated: 03/06/2021
-
List item
Human medicine European public assessment report (EPAR): Kesimpta (updated)
ofatumumab, Multiple Sclerosis, Relapsing-Remitting
Date of authorisation: 26/03/2021,, Revision: 1, Authorised, Last updated: 02/06/2021
-
List item
Human medicine European public assessment report (EPAR): Ponvory (updated)
ponesimod, Multiple Sclerosis, Relapsing-Remitting
Date of authorisation: 19/05/2021,, Authorised, Last updated: 02/06/2021
-
List item
Human medicine European public assessment report (EPAR): Truxima (updated)
rituximab, Lymphoma, Non-Hodgkin, Arthritis, Rheumatoid, Wegener Granulomatosis, Leukemia, Lymphocytic, Chronic, B-Cell, Microscopic Polyangiitis
Date of authorisation: 17/02/2017,, 
, Revision: 11, Authorised, Last updated: 02/06/2021
-
List item
Human medicine European public assessment report (EPAR): Amsparity (updated)
adalimumab, Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Psoriasis, Arthritis, Psoriatic, Spondylitis, Ankylosing, Uveitis, Colitis, Ulcerative, Crohn Disease, Hidradenitis Suppurativa
Date of authorisation: 13/02/2020,, , Revision: 2, Authorised, Last updated: 31/05/2021
-
List item
Human medicine European public assessment report (EPAR): Xermelo (updated)
telotristat etiprate, Carcinoid Tumor, Neuroendocrine Tumors
Date of authorisation: 17/09/2017,, , Revision: 12, Authorised, Last updated: 31/05/2021
-
List item
Human medicine European public assessment report (EPAR): Vaxchora (updated)
vibrio cholerae, strain cvd 103-hgr, live, Cholera
Date of authorisation: 01/04/2020,, Revision: 3, Authorised, Last updated: 27/05/2021
-
List item
Human medicine European public assessment report (EPAR): Piqray (updated)
Alpelisib, Breast Neoplasms
Date of authorisation: 27/07/2020,, Revision: 4, Authorised, Last updated: 26/05/2021
-
List item
Human medicine European public assessment report (EPAR): Tukysa (updated)
Tucatinib, Breast Neoplasms, Neoplasm Metastasis
Date of authorisation: 11/02/2021,, Revision: 1, Authorised, Last updated: 26/05/2021
-
List item
Human medicine European public assessment report (EPAR): Lemtrada (updated)
alemtuzumab, Multiple Sclerosis
Date of authorisation: 12/09/2013,, , Revision: 12, Authorised, Last updated: 25/05/2021
-
List item
Human medicine European public assessment report (EPAR): Kaftrio (updated)
ivacaftor, tezacaftor, elexacaftor, Cystic Fibrosis
Date of authorisation: 21/08/2020,, , Revision: 3, Authorised, Last updated: 25/05/2021
-
List item
Human medicine European public assessment report (EPAR): SomaKit TOC (updated)
edotreotide, Neuroendocrine Tumors, Radionuclide Imaging
Date of authorisation: 08/12/2016,, , Revision: 7, Authorised, Last updated: 25/05/2021
-
List item
Human medicine European public assessment report (EPAR): Pelgraz (updated)
pegfilgrastim, Neutropenia
Date of authorisation: 21/09/2018,, , Revision: 6, Authorised, Last updated: 25/05/2021
-
List item
Human medicine European public assessment report (EPAR): Enhertu (updated)
trastuzumab deruxtecan, Breast Neoplasms
Date of authorisation: 18/01/2021,, , Revision: 1, Authorised, Last updated: 25/05/2021
-
List item
Human medicine European public assessment report (EPAR): Jinarc (updated)
Tolvaptan, Polycystic Kidney, Autosomal Dominant
Date of authorisation: 27/05/2015,, Revision: 17, Authorised, Last updated: 25/05/2021